Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Benzoxazolooxazinones as factor xa inhibitors

A kind of compound, the technology of phenyl, be applied in the field of new benzoxazolo oxazinone compound, can solve the problem such as no teaching, do not have coagulation factor Xa inhibition effect etc.

Active Publication Date: 2018-06-26
NCPC NEW DRUG RES & DEV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] However, this compound does not have an inhibitory effect on blood coagulation factor Xa, and WO2011 / 147259 has no relevant teaching in this regard

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzoxazolooxazinones as factor xa inhibitors
  • Benzoxazolooxazinones as factor xa inhibitors
  • Benzoxazolooxazinones as factor xa inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0221] 5-chloro-N-(((3S,3aS)-1-oxo-7-(3-oxomorpholino)-1,3,3a,4-tetrahydrobenzo[b]oxazolo [3,4-d][1,4]oxazin-3-yl)methyl)thiophene-2-carboxamide

[0222]

[0223] Reaction flow:

[0224]

[0225] Step A: Cool a solution of (Z)-but-2-ene-1,4-diol (39.7g, 450mmol) in dry THF (300mL) to 0°C, add sodium hydride (60% dissolved in mineral oil) in batches , 9.0 g, 225 mmol), then a dry THF solution (450 mL) of 4-bromo-2-fluoro-1-nitrobenzene (33.0 g, 150 mmol) was added dropwise at 0°C. The reaction solution was stirred at room temperature for two hours, poured into 600 mL of water, the mixture was extracted with EtOAc, the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give (Z)-4-(5-bromo-2-nitrobenzene oxy)but-2-en-1-ol (45 g), yellow solid. The crude product was used in the next step without further purification.

[0226] Step B: Add zinc powder (49.0g, 750mmol) and ammonium chloride (40.0g, 750mmol) into methanol (450mL)...

Embodiment 2

[0238] 5-chloro-N-(((3S,3aS)-1-oxo-7-(2-oxopiperidin-1-yl)-1,3,3a,4-tetrahydrobenzo[b]oxa azole And[3,4-d][1,4]oxazin-3-yl)methyl)thiophene-2-carboxamide

[0239]

[0240] Step A: Preparation of (3R,3aS)-3-((tert-butyldimethylsilyloxy)methyl)-7-(2-oxopiperidin-1-yl)-3α according to Example 1, 4-Dihydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-1(3H)-one, 7% yield, wherein the morpholin-3 in step G -one is replaced by piperidin-2-one. LCMS (ESI) m / z: 433.2 (M+1).

[0241] Step B: The title compound of Example 2 was prepared sequentially according to Example 1 Steps G, I, J, K and L as a white solid. 1 HNMR (400MHz, DMSO-d 6 )δ9.01(t, J=5.6Hz, 1H), 7.83(d, J=8.8Hz, 1H), 7.72(d, J=4.0Hz, 1H), 7.22(d, J=4.0Hz, 1H) , 6.87-6.93(m, 2H), 4.50-4.64(m, 2H), 3.99-4.13(m, 2H), 3.73(t, J=5.6Hz, 2H), 3.52-3.60(m, 2H), 2.37 (t, J=6.0Hz, 2H), 1.77-1.90 (m, 4H); LCMS (ESI) m / z: 462.1 (M+1).

Embodiment 3

[0243] 5-chloro-N-(((3S,3aS)-1-oxo-7-(5-oxo-1,4-oxazepan-4-yl)-1,3,3a, 4- Tetrahydrobenzo[b]oxazol[3,4-d][1,4]oxazin-3-yl)methyl)thiophene-2-carboxamide

[0244]

[0245] Step A: Preparation of (3R,3aS)-3-(((tert-butyldimethylsilyl)oxy)methyl)-7-(5-oxo-1,4-oxa according to Example 1 Azepan-4-yl)-3a,4-dihydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-1(3H)-one, wherein the step The morpholin-3-one in G was replaced by 1,4-oxazepan-5-one, the yield was 35%. LCMS (ESI) m / z: 449.2 (M+1).

[0246] Step B: The title compound of Example 3 was prepared sequentially according to Example 1 Steps G, I, J, K and L as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ9.01(s, 1H), 7.82(d, J=8.4Hz, 1H), 7.72(d, J=4.0Hz, 1H), 7.22(d, J=4.0Hz, 1H), 6.87-6.83( m, 2H), 4.60-4.54(m, 2H), 4.10-4.00(m, 2H), 3.80-3.65(m, 8H), 2.78(t, J=4.8Hz, 2H); LCMS (ESI) m / z: 478.1(M+1).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new compound of formula (I) or its solvate, hydrate, tautomer, or pharmaceutically acceptable salt, wherein R1 represents substituted or unsubstituted aryl or heteroaryl; R2 Represents an optionally substituted 3‑9 membered carbocycle or heterocycle, etc.; R3 represents H, etc.; A is selected from O, NH, N‑CH3, S, SO, SO2, and CH2; X, Y, and Z are independently selected from From CH, C-Br, C-Cl, C-F, C-I and N. The compound of the present invention can be used as an anticoagulant for treating and preventing abnormal thrombus diseases, and the present invention satisfies the actual demand for a selective and potent inhibitor of coagulation factor Xa by providing a potent inhibitor of coagulation factor Xa.

Description

technical field [0001] The present invention relates to a new benzoxazoloxazinone compound, especially a compound represented by formula (I), its preparation method, pharmaceutical composition and its use as an anticoagulant in the treatment and prevention of thromboembolic diseases. Background technique [0002] Cardiovascular disease is the leading cause of morbidity and mortality in the developed world population, with the majority of cardiovascular events primarily attributable to thrombosis. Warfarin is the first oral anticoagulant approved for marketing, and its application suffers from slow vitamin K-dependent antagonism, drug-drug interactions, and drug-food interactions, which lead to Continuous monitoring is required for accurate dosing. Other anticoagulants such as heparin and fondaparinux are only suitable for parenteral administration. The above-mentioned defects of existing anticoagulants have promoted the in-depth research of new anticoagulant drugs. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D519/00C07D498/14C07D513/04A61K31/5383A61K31/553A61K31/5386A61K31/541A61K31/542A61P7/02A61P9/10
CPCA61P7/02A61P9/10C07D498/04C07D498/14C07D513/04
Inventor 高任龙丁照中赖光华陈曙辉颜小兵段宝玲朱秀良路新华胡军平
Owner NCPC NEW DRUG RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com